Daniel M Harvey

Address:

16013 N 4 Ave, Phoenix, AZ 85023

VIN:

1GCEC19X67Z109524

Make:

CHEVROLET

Model:

SILVERADO 1500 CLASSIC

Year:

2007

US Patent:

7335648, Feb 26, 2008

Filed:

May 5, 2005

Appl. No.:

11/124619

Inventors:

Robert Plourde, Jr. - Chapel Hill NC, US
Sammy R. Shaver - Chapel Hill NC, US
Paul S. Watson - Carrboro NC, US
José L. Boyer - Chapel Hill NC, US
Chi Tu - San Diego CA, US
Melwyn A. Abreo - Jamul CA, US
Lorenzo J. Alfaro-Lopez - San Marcos CA, US
Yangbo Feng - Palm Beach Gardens FL, US
Daniel F. Harvey - San Diego CA, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

A01N 43/04
A61K 31/70
C07H 19/16

US Classification:

514 46, 536 2723

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

US Patent:

7368438, May 6, 2008

Filed:

Oct 21, 2004

Appl. No.:

10/971766

Inventors:

Robert Plourde, Jr. - Chapel Hill NC, US
Sammy R. Shaver - Chapel Hill NC, US
José L. Boyer - Chapel Hill NC, US
Melwyn A. Abreo - Jamul CA, US
Lorenzo J. Alfaro-Lopez - San Marcos CA, US
Yangbo Feng - Palm Beach Gardens FL, US
Daniel F. Harvey - San Diego CA, US
Chi Tu - San Diego CA, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

A01N 43/04
A61K 31/70
C07H 19/16

US Classification:

514 46, 536 2723

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Yreceptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.

US Patent:

7390813, Jun 24, 2008

Filed:

Dec 20, 2002

Appl. No.:

10/326210

Inventors:

Michael D. Winther - Vancouver, CA
Richard M. Fine - Ridgewood NJ, US
Boris Klebansky - Demarest NJ, US
Heinz Gschwend - Santa Rosa CA, US
Daniel F. Harvey - San Diego CA, US

Assignee:

Xenon Pharmaceuticals Inc. - Burnaby, BC

International Classification:

A61K 31/495
C07D 401/04

US Classification:

514255, 544360

Abstract:

Novel compounds useful in the treatment of, prevention of or protection against diseases and/or conditions related to metabolic syndrome and lipid metabolism, especially diseases of fatty acid and cholesterol metabolism, such as those mediated by stearoyl-CoA desaturase, are disclosed along with methods of employing said compounds for such uses.

US Patent:

7592445, Sep 22, 2009

Filed:

Jan 4, 2008

Appl. No.:

11/969539

Inventors:

Robert Plourde, Jr. - Chapel Hill NC, US
Sammy R. Shaver - Chapel Hill NC, US
Paul S. Watson - Carrboro NC, US
José L. Boyer - Chapel Hill NC, US
Chi Tu - San Diego CA, US
Melwyn A. Abreo - Jamul CA, US
Lorenzo J. Alfaro-Lopez - San Marcos CA, US
Yangbo Feng - Palm Beach Gardens FL, US
Daniel F. Harvey - San Diego CA, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

C07H 19/16
A01N 43/04
A61K 31/70

US Classification:

536 273, 514 46

Abstract:

This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.

US Patent:

7605161, Oct 20, 2009

Filed:

Jul 29, 2004

Appl. No.:

10/566193

Inventors:

Melwyn Abreo - Jamul CA, US
Daniel F. Harvey - San Diego CA, US
Heinz W. Gschwend - Santa Rosa CA, US
Wenbao Li - San Diego CA, US
Chi Tu - San Diego CA, US
Rajender Kamboj - Burnaby, CA
Michael D. Winther - Vancouver, CA
Vishnumurthy Kodumuru - Burnaby, CA
Cindy J. Hudson - Buena Park CA, US
Mikhail A. Kondratenko - San Diego CA, US
Shifeng Liu - Port Coquitlam, CA
Vandna Raina - Vancouver, CA
Serguei Sviridov - Burnaby, CA
Zaihui Zhang - Vancouver, CA
Mehran Seid Bagherzadeh - North Vancouver, CA
Shaoyi Sun - Vancouver, CA

Assignee:

Xenon Pharmaceuticals Inc. - Burnaby, British Columbia

International Classification:

A61K 31/497
C07D 241/04
C07D 295/00

US Classification:

51425212, 544358

Abstract:

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein: W is —O—, —N(R1)—, C(O), S(O)t; (where t is 0, 1 or 2), N(R1)S(O)2, S(O)2N(R1), C(O)N(R1) or N(R1)C(O)N(R1); and V is C(O), C(S), C(O)N(R1)—, C(O)O—, S(O)2—, S(O)2N(R1)— or C(R11)H; and x, y, R1, R2, R3, R4, R5, R6, R7, R7, R8, R8, R9, R9, R10 and R10are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

US Patent:

7763618, Jul 27, 2010

Filed:

Jul 29, 2004

Appl. No.:

10/566857

Inventors:

Melwyn Abreo - Jamul CA, US
Daniel F. Harvey - San Diego CA, US
Mikhail A. Kondratenko - San Diego CA, US
Wenbao Li - San Diego CA, US
Rajender Kamboj - Burnaby, CA
Vishnumurthy Kodumuru - Burnaby, CA
Michael D. Winther - Vancouver, CA
Heinz W. Gschwend - Santa Rosa CA, US
Nagasree Chakka - Burnaby CA, US
Shifeng Liu - Port Coquitlam, CA
Serguei Sviridov - Burnaby CA, US
Shaoyi Sun - Vancouver, CA

Assignee:

Xenon Pharmaceuticals Inc. - Burnaby, British Columbia

International Classification:

A61K 31/497
C07D 241/04
C07D 295/00

US Classification:

51425212, 544358

Abstract:

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein W, V, x, y, R, R, R, R, R, R, R, Ra, R, Ra, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

US Patent:

7919484, Apr 5, 2011

Filed:

Feb 8, 2006

Appl. No.:

11/815739

Inventors:

Rajender Kamboj - Burnaby, CA
Michael D. Winther - Vancouver, CA
Robert Fraser - Vancouver, CA
Mikhail Chafeev - Burnaby, CA
Sultan Chowdhury - Surrey, CA
Jian-Min Fu - Burnaby, CA
Duanjie Hou - Burnaby, CA
Shifeng Liu - Port Coquitlam, CA
Vandna Raina - Vancouver, CA
Mehran Seid Bagherzadeh - North Vancouver, CA
Serguei Sviridov - Burnaby, CA
Kashinath Sadalapure - Edmonton, CA
Shaoyi Sun - Vancouver, CA
Vishnumurthy Kodumuru - Burnaby, CA
Nagasree Chakka - Burnaby, CA
Zaihui Zhang - Vancouver, CA
Melwyn Abreo - Jamul, CA
Mikhail A. Kondratenko - San Diego CA, US
Daniel F. Harvey - San Diego CA, US
Cindy J. Hudson - Buena Park CA, US
Wenbao Li - San Diego CA, US
Chi Tu - San Diego CA, US
Sengen Sun - San Diego CA, US
Mark W. Holladay - San Diego CA, US
Heinz W. Gschwend - Santa Rosa CA, US

Assignee:

Xenon Pharmaceuticals Inc. - Burnaby, British Columbia

International Classification:

A61K 31/501
C07D 211/34

US Classification:

514183, 544238, 54425202

Abstract:

This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.

US Patent:

7943760, May 17, 2011

Filed:

Sep 2, 2009

Appl. No.:

12/552465

Inventors:

Robert Plourde, Jr. - Chapel Hill NC, US
Sammy R. Shaver - Chapel Hill NC, US
Paul S. Watson - Carrboro NC, US
José L. Boyer - Chapel Hill NC, US
Chi Tu - San Diego CA, US
Melwyn A. Abreo - Jamul CA, US
Lorenzo J. Alfaro-Lopez - San Marcos CA, US
Yangbo Feng - Palm Beach Gardens FL, US
Daniel F. Harvey - San Diego CA, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

C07H 19/16
A01N 43/04
A61K 31/70

US Classification:

536 273, 514 46

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Yreceptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.